| Benign multiple sclerosis: a distinct clinical entity with therapeutic implications. | |
| | |
MedLine Citation:
|
PMID: 18219812 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This chapter describes the natural history of multiple sclerosis and, in particular, reviews the controversy regarding the entity of benign multiple sclerosis. Based on the Olmsted County population prevalence cohort study performed at the Mayo Clinic, MS patients with EDSS scores of 2 or lower followed for a period of 5-10 years have a very small risk of developing disability over the next 10-20 years. Based on these findings, this chapter reviews the indications, efficacy, mode of action, and side effect profiles of the currently approved and available disease-modifying agents for the treatment of multiple sclerosis. The efficacy of these agents is discussed based on the concepts of evidence-based medicine and the natural history of the disease. We review the arguments for and against treating all patients with MS. The authors propose an individualized approach to the use of these agents in the MS population. |
| | |
Authors:
|
S J Pittock; M Rodriguez |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current topics in microbiology and immunology Volume: 318 ISSN: 0070-217X ISO Abbreviation: Curr. Top. Microbiol. Immunol. Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-01-28 Completed Date: 2008-02-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0110513 Medline TA: Curr Top Microbiol Immunol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1-17 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. pittock.sean@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Brain / radiography Humans Interferon-beta / therapeutic use* Magnetic Resonance Imaging Mitoxantrone / therapeutic use* Multiple Sclerosis / drug therapy*, physiopathology*, radiography Peptides / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Peptides; 0/copolymer 1; 0/natalizumab; 65271-80-9/Mitoxantrone; 77238-31-4/Interferon-beta |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of copper metal on the yield of Sc3N@C80 metallofullerenes.
Next Document: Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders...